The Subtypes of Rosacea: Implications for Treatment

Cutis

Volumn 73, Issue 1 SUPPL., 2004, Pages 9-14

  Odom, Richard B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMPICILLIN; ANTIBIOTIC AGENT; AZELAIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CALCINEURIN; CLINDAMYCIN PHOSPHATE; CLONIDINE; DOXYCYCLINE; ISOTRETINOIN; LYMECYCLINE; MACROLIDE; METRONIDAZOLE; MINOCYCLINE; NADOLOL; PIMECROLIMUS; PROSTAGLANDIN; SULFACETAMIDE; SULFUR DERIVATIVE; TETRACYCLINE; TETRACYCLINE DERIVATIVE; TSUKUBAENOLIDE;

ATOPIC DERMATITIS; CLINICAL TRIAL; CONFERENCE PAPER; CYTOKINE RELEASE; DISEASE CLASSIFICATION; DRUG FORMULATION; ERYTHEMA; FLUSHING; HUMAN; LOW DRUG DOSE; PAPULE; PULSED DYE LASER; ROSACEA; SIGNAL TRANSDUCTION; SKIN SURGERY; TELANGIECTASIA;

DIAGNOSIS, DIFFERENTIAL; EVIDENCE-BASED MEDICINE; HUMANS; RANDOMIZED CONTROLLED TRIALS; ROSACEA;

EID: 0842330450     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (42)

1. McClellan KJ, Nobel S. Topical metronidazole. a review of its use in rosacea. Am J Clin Dermatol. 2000;3:191-199.
2. Bikowski JB. Rosacea: a tiered approach to therapy. Cutis. 2000;66(suppl 4):3-6.
3. Webster GF. Treatment of rosacea. Semin Cutan Med Surg. 2001;20:207-208.
4. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46:584-587.
5. Sugarman JH, Fleischer AB Jr, Feldman SR. Off-label prescribing in the treatment of dermatologic disease. J Am Acad Dermatol. 2002;47:217-223.
6. Dellavalle RP, Stegner DL, Deas AM, et al. Assessing evidence-based dermatology and evidence-based internal medicine curricula in US residency training programs: a national survey. Arch Dermatol. 2003;139:369-372.
7. Guyatt GH, Sackett DL, Sinclair JC, et al. Users' guides to the medical literature, XXV. evidence-based medicine: principles for applying the users' guide to patient care. JAMA. 2000;284:1290-1296.
8. Michaelsson G. Effects of antihistamines, acetylsalicylic acid and prednisone on cutaneous reactions to kallikrein and prostaglandin E1. Acta Derm Venereol. 1970;50:31-36.
9. Guarrera M, Parodi A, Cipriani C, et al. Flushing in rosacea: a possible mechanism. Arch Dermatol Res. 1982;272:311-316.
10. Wilkin JK. Effect of nadolol on flushing reactions in rosacea. J Am Acad Dermatol. 1989;20:202-205.
11. Wilkin JK. Effect of subdepressor clonidine on flushing reactions in rosacea. change in malar thermal circulation index during provoked flushing reactions. Arch Dermatol. 1983;119:211-214.
12. Kalthoff F, Meingassner JG, Chung J, et al. Pimecrolimus is more selective than corticosteroids on dendritic cells. In: Abstracts of the American Academy of Dermatology 61st Annual Meeting; March 21-26, 2003; San Francisco, California. Abstract P17.
13. Koo JYM, Fleischer A, Pariser D, et al. Tacrolimus ointment 0.1% is safe and effective in the treatment for atopic dermatitis: final results of a large (over 7,000 patients) open-label study. In: Abstracts of the American Academy of Dermatology 61st Annual Meeting; March 21-26, 2003; San Francisco, California. Abstract P22.
14. Bergman J, Rico J. Tacrolimus clinical studies for atopic dermatitis and other conditions. Semin Cutan Med Surg. 2001;20:250-259.
15. Gulliver WP. Tacrolimus 0.1% ointment is useful in treating rosacea patients with seborrheic dermatitis. In: Abstracts of the American Academy of Dermatology 61st Annual Meeting; March 21-26, 2003; San Francisco, California. Abstract P90.
16. Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol. 2001;44:995-998.
17. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48:836-845.
18. Breneman DL, Stewart D, Hevia O, et al. A double-blind, multicenter clinical trial comparing efficacy of once-daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis. 1998;61:44-47.
19. Bleicher PA, Charles JH, Sober AJ. Topical metronidazole therapy for rosacea. Arch Dermatol. 1987;123:609-614.
20. Jorizzo JL, Lebwohl M, Tobey RE. The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double-blind clinical trial. J Am Acad Dermatol. 1998;39:502-504.
21. Taub AF. Treatment of rosacea with intense pulsed light. J Drugs Dermatol. 2003;2:254-259.
22. Mark KA, Sparacio RM, Voigt A, et al. Objective and quantitative improvement of rosacea-associated erythema after intense pulsed light treatment. Dermatol Surg. 2003;29:600-604.
23. Clark SM, Lanigan SW, Marks R. Laser treatment of erythema and telangiectasia associated with rosacea. Lasers Med Sci. 2002;17:26-33.
24. Veien NK, Christiansen JV, Hjorth N, et al. Topical metronidazole in the treatment of rosacea. Cutis. 1986;38:209-210.
25. Aronson IK, Rumsfield JA, West DP, et al. Evaluation of topical metronidazole gel in acne rosacea. Drug Intell Clin Pharm. 1987;21:346-351.
26. Dahl MV, Jarratt M, Kaplan D, et al. Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea. J Am Acad Dermatol. 2001;45:723-730.
27. Dahl MV, Katz I, Krueger GG, et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol. 1998;134:679-683.
28. Nielsen PG. A double-blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. Br J Dermatol. 1983;109:63-65.
29. Marks R, Ellis J. Comparative effectiveness of tetracycline and ampicillin in rosacea. a controlled trial. Lancet. 1971;2:1049-1052.
30. Drake L, Leyden JJ, Lucky A, et al. Evaluation of topical metronidazole cream in rosacea. In: Abstracts of the American Academy of Dermatology 55th Annual Meeting; March 21-26, 1997; San Francisco, California. Abstract P65.
31. Del Rosso JQ. Systemic therapy for rosacea: focus on oral antibiotic therapy and safety. Cutis. 2000;66(suppl 4):7-13.
32. Del Rosso JQ. A status report on the medical management of rosacea: focus on topical therapies. Cutis. 2002;70:271-275.
33. Sauder DN, Miller R, Gratton D, et al. The treatment of rosacea: the safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion (Novacet) is demonstrated in a double-blind study. J Dermatol Treat. 1997;8:79-85.
34. Lebwohl MG, Medansky RS, Russo CL, et al. The comparative efficacy of sodium sulfacetamide 10%/sulfur 5% (Sulfacet-R®) lotion and metronidazole 0.75% (Metro-Gel) in the treatment of rosacea. J Geriatr Dermatol. 1993;3:183-185.
35. Elewski B. A comparison of topical azelaic acid 15% gel and metronidazole 0.75% gel in the treatment of papulopustular facial rosacea: results of a 15-week, randomized, double-blind, multicenter study. In: Abstracts of the American Academy of Dermatology 61st Annual Meeting; March 21-26, 2003; San Francisco, California. Abstract P50.
36. Erdogan FG, Yurtsever P, Aksoy D, et al. Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol. 1998;134:884-885.
37. Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol. 1994;130:319-324.
38. Curnier A, Choudhary S. Triple approach to rhinophyma. Ann Plast Surg. 2002;49:211-214.
39. Bogetti P, Boltri M, Spagnoli G, et al. Surgical treatment of rhinophyma: a comparison of techniques. Aesthetic Plast Surg. 2002;26:57-60.
40. Frucht-Pery J, Sagi E, Hemo I, et al. Efficacy of doxycycline and tetracycline in ocular rosacea. Am J Ophthalmol. 1993;116:88-92.
41. Quarterman MJ, Johnson DW, Abele DC, et al. Ocular rosacea. Signs, symptoms, and tear studies before and after treatment with doxycycline. Arch Dermatol. 1997;133:49-54.
42. Gupta AK. The strength of the evidence for various therapies in the management of rosacea. In: Abstracts of the American Academy of Dermatology 61st Annual Meeting; March 21-26, 2003; San Francisco, California. Abstract P54.